An announcement from Aptose Biosciences ( (TSE:APS)) is now available. Aptose Biosciences Inc., a clinical-stage biotech developer of precision oncology drugs focused on hematologic malignancies, is ...

Laurel Loomis Rimon examines the new rules recently issued by the Financial Crimes Enforcement Network aimed at countering ...

According to a TRM Labs report, illicit flows reached about $154–158 billion in 2025, and regulators increased pressure ...

KuCoin got slapped. Hard. The Austrian Financial Market Authority told the exchange to stop serving European Union customers ...

Japan warns that unregistered crypto use in property deals may breach law and orders stricter AML checks for real estate ...

Sellas Life Sciences shares rose after Commonwealth Equity Services boosted its stake ahead of a key Phase 3 AML trial milestone, joining other major institutional investors in increasing holdings.

The firms AMLA will supervise directly are the firms most exposed to the jurisdictional complexity that makes contextual ...

BridgeTower taps Chainlink to tokenize $11B+ in DOM X securities with CCIP, NAVLink, reserve checks, and compliance tools at ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.

Dr Janet Bastiman discusses the future of AI for AML and offers expert guidance on how best to collaborate with the FCA and ...

The latest update keeps Dye & Durham’s central fair value at CA$5.00, while analyst price targets remain tightly grouped between CA$4 and CA$5. That split reflects a careful balance between cautious ...